VEGFA and hepatocellular carcinoma: Among them, five were TKI/anti-VEGF cohorts (REACH, REACH-2, METIV-HCC, CELESTIAL, and JET-HCC) and three were immunotherapy cohorts (Checkmate 459, IMbrave150, and KEYNOTE-240).